Booming Healthcare sector in MENA Region
MENA will be home to nearly 700 million people by 2020 —an increase in GDP per capita income, improved literacy, and a sizable middle class are the strong drivers fueling the growth of multi-diverse markets in the MENA region. Healthcare is one such emerging market, which has shown significant growth, particularly in the GCC region.
The Middle Eastern markets are a hotbed for foreign investors as it brings immense opportunities to satiate a rise in demand in the state-of-the-art pharmaceutical and medical devices. As each member state has a different regulatory environment for medical devices, to diversify their business, investors need to remain adaptive by orienting themselves with the various regulatory protocols, licensing rules, reimbursement systems, and negotiation techniques.
To read more on the Booming Healthcare sector in MENA visit https://www.delveinsight.com/blog/booming-healthcare-sector-in-mena-region/ or refer to Delveinsight.
Wet Age-related Macular Degeneration Market
As per DelveInsight Business Research LLP analysis, of all the Wet Age-related Macular Degeneration emerging therapies, the most anticipated product to get launched is Abicipar Pegol, a lead candidate of Allergan.
Several other emerging #therapies such as GB-102 by Graybug Vision, Inc., ALK4290 by Alkahest, Inc., Vorolanib by EyePoint Pharmaceuticals, IBI 302 by Innovent Biologics（信达生物制药）and FYB201 by Bbioeq GmbH are also expected to shift the Wet Age-related macular degeneration landscape positively.
For more details visit: https://www.delveinsight.com/blog/wet-age-related-macular-degeneration-treatment-market/
#market #marketresearch #pharma #biotech #lifescience #medical #healthcare #maculardegeneration
Wuhan Coronavirus: A global emergency
Despite strict travel guidelines, and restricted movement to and from- China, the caseloads of Wuhan Coronavirus are increasing at an alarming rate, with suspected cases now been confirmed, and a cloud of uncertainty on the number of deaths it may cause, looming. With the infected cases totalling to 45,168, and the deaths around 1,115- surpassing the death rate reported at the time of Severe acute respiratory syndrome (#SARS)- the novel Coronavirus has now come to know as Coronavirus disease 2019 (COVID-19). Therapies, which Pharma companies are reportedly working on, and have the potential to cure the coronavirus epidemic are: Noravax MERS, Invio’s INO-4700, Biocryst’s Galidesivir, AbbVie’s Lopinavir HIV inhibitor, Regeneron’s REGN3048-3051. To read more about coronavirus, visit: https://www.delveinsight.com/blog/coronavirus/ or https://www.delveinsight.com/blog/coronavirus-2019-ncov-is-now-covid-19/
Wet Age-Related Macular Degeneration
As per the BrightFocus Foundation, nearly 11 million Americans are living with one or other type of Age-Related Macular degeneration (AMD). With approximately 200,000 diagnoses of new cases of Wet Age-Related Macular Degenerationeach year in the U.S., Wet Age-Related Macular Degeneration, also known as neovascular or exudative Wet Age-Related Macular D
egeneration, affects around 1.1 million of the Americans.
Several emerging therapies such as Abicipar Pegol by Allergan, Brolucizumab by Novartis, GB-102 by Graybug Vision, Inc., ALK4290 by Alkahest, Inc., Vorolanib by EyePoint Pharmaceuticals, and FYB201 by Bioeq GmbH are expected to shift the Wet Age-related macular degeneration landscape positively.
Visit to read more: https://www.delveinsight.com/blog/wet-age-related-macular-degeneration/
#pharma #biotech #healthcare #medical #macular #market #marketresearch #lifescience #health
Joined Feb 2020
